More recently, Carrabotta et al. highlighted an HMGA2/IGF2BP/IGF2/IGF1R/AKT/mTOR axis that characterizes CIC-DUX4 sarcomas and renders the tumors particularly sensitive to combined treatments with trabectedin and PI3K/mTOR inhibitors such as NVP-BEZ235 [39]. Here, HMGA2 is linked to sarcoma.